Pituitary hypophysitis in granulomatosis with polyangiitis (GPA): a case series

Majid Alameri,Abdulla Alnuaimi,Niamh M. Martin,Karim Meeran,Anastasia Gontsarova,Tara D. Barwick,Spencer Ellis,Stephen McAdoo,James Tomlinson,Florian Wernig
DOI: https://doi.org/10.1007/s11102-023-01378-5
2024-02-03
Pituitary
Abstract:Granulomatosis with polyangiitis (GPA) rarely involves the pituitary gland. Pituitary involvement has been reported in ~ 1% of all cases of GPA. Most commonly, pituitary swelling and inflammation results in symptoms due to pituitary mass effect and arginine vasopressin deficiency. To date, there are no pituitary-specific treatment guidelines for this rare condition. We present three patients with GPA-related hypophysitis highlighting the spectrum of pituitary involvement. All three patients were successfully treated with immunosuppressive regimens that included rituximab (RTX). Following remission induction with high-dose glucocorticoids, patients received 6 monthly RTX for remission maintenance. RTX was well tolerated without significant side effects.
endocrinology & metabolism
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve The paper attempts to address the issues related to the diagnosis and treatment of **granulomatosis with polyangiitis (GPA)-associated hypophysitis**. Specifically: 1. **Rarity Issue**: GPA rarely involves the pituitary gland, with a reported incidence of about 1% in the literature. When the pituitary is affected, it usually presents with pituitary swelling and inflammation, leading to symptoms such as headaches, visual disturbances, and antidiuretic hormone (ADH) deficiency. 2. **Lack of Treatment Guidelines**: Currently, there are no specific treatment guidelines for GPA-associated hypophysitis. Therefore, effectively managing and treating this rare condition is an urgent issue that needs to be addressed. 3. **Case Analysis**: The paper presents a case series of three patients with GPA-associated hypophysitis, demonstrating their clinical presentations and treatment outcomes after using immunosuppressants, particularly rituximab (RTX). ### Main Findings 1. **Diagnostic Methods**: The diagnosis of GPA-associated hypophysitis primarily relies on clinical symptoms, imaging studies (such as MRI), and serological markers (such as PR3-ANCA). 2. **Treatment Regimen**: All three patients successfully received immunosuppressive therapy primarily consisting of high-dose glucocorticoids and rituximab (RTX). After inducing remission, the patients continued to receive RTX maintenance therapy every 6 months. 3. **Efficacy Evaluation**: Post-treatment, the patients' pituitary lesions significantly reduced, clinical symptoms improved, and no severe side effects were observed. However, some patients still required long-term supplementation with antidiuretic hormone (DDAVP). ### Conclusion 1. **Treatment Efficacy**: High-dose glucocorticoids combined with RTX have shown high efficacy and good tolerance in inducing and maintaining remission of GPA-associated hypophysitis. 2. **Need for Further Research**: Although this case series provides preliminary evidence, more clinical studies are needed to determine the most effective treatment regimen. ### Limitations 1. **Data Quality**: Due to the rarity of GPA-associated hypophysitis, the quality of data in the existing literature is poor. 2. **Small Sample Size**: The number of cases in this study is small, and larger-scale trials are needed to verify the efficacy of the treatment regimen. Through these findings, the paper provides valuable references for the clinical management of GPA-associated hypophysitis, while also pointing out directions for future research.